Reducing immune tolerance induced by PD-L1
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 14, 2020
Grant Date -
Apr 6, 2017
app pub date -
Dec 8, 2016
filing date -
Mar 2, 2015
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully